X0306 4 2018-10-12 0 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001458753 Ross Leonard S C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 0 1 0 0 See Remarks Common Stock 2018-10-12 4 A 0 20000 0.00 A 34762 D Common Stock 2018-10-12 4 F 0 2945 3.23 D 31817 D On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 10,000 shares representing a previously granted performance stock unit award vested on that date. An additional 10,000 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the performance stock units. Vice President of Finance and Chief Accounting Officer /s/ John Mercer, Attorney-in-Fact 2018-10-16